These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 10583024)

  • 1. The effect of dosing regimen on the pharmacokinetics of risedronate.
    Mitchell DY; Heise MA; Pallone KA; Clay ME; Nesbitt JD; Russell DA; Melson CW
    Br J Clin Pharmacol; 1999 Oct; 48(4):536-42. PubMed ID: 10583024
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risedronate gastrointestinal absorption is independent of site and rate of administration.
    Mitchell DY; Eusebio RA; Dunlap LE; Pallone KA; Nesbitt JD; Russell DA; Clay ME; Bekker PJ
    Pharm Res; 1998 Feb; 15(2):228-32. PubMed ID: 9523308
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical trial of risedronate in Japanese volunteers: a study on the effects of timing of dosing on absorption.
    Ogura Y; Gonsho A; Cyong JC; Orimo H
    J Bone Miner Metab; 2004; 22(2):120-6. PubMed ID: 14999522
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dose-proportional pharmacokinetics of risedronate on single-dose oral administration to healthy volunteers.
    Mitchell DY; Eusebio RA; Sacco-Gibson NA; Pallone KA; Kelly SC; Nesbitt JD; Brezovic CP; Thompson GA; Powell JH
    J Clin Pharmacol; 2000 Mar; 40(3):258-65. PubMed ID: 10709154
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of renal function on risedronate pharmacokinetics after a single oral dose.
    Mitchell DY; St Peter JV; Eusebio RA; Pallone KA; Kelly SC; Russell DA; Nesbitt JD; Thompson GA; Powell JH
    Br J Clin Pharmacol; 2000 Mar; 49(3):215-22. PubMed ID: 10718776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.
    Mitchell DY; Barr WH; Eusebio RA; Stevens KA; Duke FP; Russell DA; Nesbitt JD; Powell JH; Thompson GA
    Pharm Res; 2001 Feb; 18(2):166-70. PubMed ID: 11405286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical trial of risedronate in Japanese volunteers: single and multiple oral dose studies.
    Ogura Y; Gonsho A; Cyong JC; Orimo H
    J Bone Miner Metab; 2004; 22(2):111-9. PubMed ID: 14999521
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risedronate, a highly effective, short-term oral treatment for Paget's disease: a dose-response study.
    Brown JP; Hosking DJ; Ste-Marie L; Johnston CC; Reginster J; Ryan WG; Johnson TD; Bekker PJ
    Calcif Tissue Int; 1999 Feb; 64(2):93-9. PubMed ID: 9914313
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An open-label randomized study of the relative absorption of gastro-resistant risedronate taken fasted or with food versus immediate-release risedronate.
    Kleinermans D; Joyson A; Wray H
    Pharmacol Res Perspect; 2022 Jun; 10(3):e00957. PubMed ID: 35526121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of food intake on the pharmacokinetic properties of mirabegron oral controlled-absorption system: a single-dose, randomized, crossover study in healthy adults.
    Lee J; Zhang W; Moy S; Kowalski D; Kerbusch V; van Gelderen M; Sawamoto T; Grunenberg N; Keirns J
    Clin Ther; 2013 Mar; 35(3):333-41. PubMed ID: 23497763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of matched historical controls to evaluate the anti-fracture efficacy of once-a-week risedronate.
    Watts NB; Lindsay R; Li Z; Kasibhatla C; Brown J
    Osteoporos Int; 2003 Jun; 14(5):437-41. PubMed ID: 12730756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Upper gastrointestinal tract safety of daily oral risedronate in patients taking NSAIDs: a randomized, double-blind, placebo-controlled trial.
    Adami S; Pavelka K; Cline GA; Hosterman MA; Barton IP; Cohen SB; Bensen WG
    Mayo Clin Proc; 2005 Oct; 80(10):1278-85. PubMed ID: 16212139
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of food intake on the pharmacokinetic properties of dalcetrapib: findings from three phase I, single-dose crossover studies in healthy volunteers.
    Derks M; Kawamura H; Abt M; Meneses-Lorente G; Phelan M; Ishikawa T
    Clin Ther; 2011 Jun; 33(6):754-65. PubMed ID: 21704240
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Esophageal transit of risedronate cellulose-coated tablet and gelatin capsule formulations.
    Perkins AC; Wilson CG; Frier M; Vincent RM; Blackshaw PE; Dansereau RJ; Juhlin KD; Bekker PJ; Spiller RC
    Int J Pharm; 1999 Sep; 186(2):169-75. PubMed ID: 10486435
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and tolerability of once-weekly administration of 17.5 mg risedronate in Japanese patients with involutional osteoporosis: a comparison with 2.5-mg once-daily dosage regimen.
    Kishimoto H; Fukunaga M; Kushida K; Shiraki M; Itabashi A; Nawata H; Nakamura T; Ohta H; Takaoka K; Ohashi Y;
    J Bone Miner Metab; 2006; 24(5):405-13. PubMed ID: 16937274
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.
    Godfrey AR; Digiacinto J; Davis MW
    Clin Ther; 2011 Jun; 33(6):766-75. PubMed ID: 21704241
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Monthly dosing with risedronate 50 mg on three consecutive days a month compared with daily dosing with risedronate 5 mg: a 6-month pilot study.
    Racewicz AJ; Schofield PJ; Cahall DL; Cline GA; Burgio DE
    Curr Med Res Opin; 2007 Dec; 23(12):3079-89. PubMed ID: 17971285
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risedronate for Paget's disease of bone.
    Med Lett Drugs Ther; 1998 Aug; 40(1034):87-8. PubMed ID: 9731243
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of different meal compositions and fasted state on the oral bioavailability of etravirine.
    Schöller-Gyüre M; Boffito M; Pozniak AL; Leemans R; Kakuda TN; Woodfall B; Vyncke V; Peeters M; Vandermeulen K; Hoetelmans RM
    Pharmacotherapy; 2008 Oct; 28(10):1215-22. PubMed ID: 18823217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.